Evidence map›Paper›PMID 39170614›Full record

ArticleFrontiers in immunology2024

Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low,

Nicolas Roussot, Marion Thibaudin, Jean-David Fumet, Susy Daumoine, Léa Hampe, Cédric Rébé, Emeric Limagne, Aurélie Lagrange, Victor Herreros, Julie Lecuelle and 15 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Nicolas RoussotUnité Formation Recherche (UFR) des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
Marion ThibaudinCancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Jean-David FumetUnité Formation Recherche (UFR) des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
Susy DaumoineCancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Léa HampeCancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Cédric RébéCancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Emeric LimagneUnité Formation Recherche (UFR) des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
Aurélie LagrangeDepartment of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
Victor HerrerosDepartment of Interventional Radiology, Centre Georges-François Leclerc, Dijon, France.
Julie LecuelleCancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Hugo MananetCancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Alis IlieCancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
David RageotCancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Romain BoidotCancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Vincent GoussotCancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Anthony ComteCancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Pierre JacobUnité Formation Recherche (UFR) des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
Françoise BeltjensCancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Anthony BergeronCancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Céline Charon-BarraCancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Laurent ArnouldCancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
Valentin DerangèreUnité Formation Recherche (UFR) des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
Sylvain LadoireUnité Formation Recherche (UFR) des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.
Caroline TruntzerCancer Biology Transfer Platform, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France.
François GhiringhelliUnité Formation Recherche (UFR) des Sciences de Santé, Université Bourgogne Franche-Comté, Dijon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A patient with a PD-L1-negative, TMB-low,

Indexed as

B7-H1 AntigenCarcinoma, Non-Small-Cell LungDisease ProgressionKelch-Like ECH-Associated Protein 1Lung NeoplasmsMutationBiomarkers, TumorFemaleHumansMiddle AgedB7-H1 AntigenBiomarkers, TumorCD274 protein, humanKEAP1 protein, humanKelch-Like ECH-Associated Protein 1case reportchemoimmunotherapycold tumormetastatic NSCLCneoantigenNSCLCpseudoprogressiontumor neoantigen

Identifiers

PMID39170614
PMCPMC11335479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.